$ME
23andMe Holding Co. Stock $me

$me Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000180459124000047 Filed on August 08, 2024

Income Statement

Concept	2024 Q2	2023 Q2
Revenue	$40.41M	$60.86M
YoY Change	-33.6%	-5.66%
Cost Of Revenue	$19.90M	$30.18M
YoY Change	-34.07%	-22.65%
Gross Profit	$20.51M	$30.68M
YoY Change	-33.14%	20.36%
Gross Profit Margin	50.76%	50.41%
Selling, General & Admin	$47.83M	$73.40M
YoY Change	-34.83%	16.36%
% of Gross Profit	233.17%	239.24%
Research & Development	$44.64M	$62.33M
YoY Change	-28.38%	19.84%
% of Gross Profit	217.59%	203.16%
Depreciation & Amortization	$2.000M	$3.000M
YoY Change	-33.33%	-68.13%
% of Gross Profit	9.75%	9.78%
Operating Expenses	$92.47M	$139.9M
YoY Change	-33.92%	21.6%
Operating Profit	-$71.96M	-$109.3M
YoY Change	-34.15%	21.95%
Interest Expense	$2.574M	$4.307M
YoY Change	-40.24%	1657.96%
% of Operating Profit
Other Income/Expense, Net	-$19.00K	$333.0K
YoY Change	-105.71%	-176.55%
Pretax Income	-$69.40M	-$104.6M
YoY Change	-33.67%	16.53%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$69.40M	-$104.6M
YoY Change	-33.67%	16.86%
Net Earnings / Revenue	-171.72%	-171.9%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.14	-$0.23
COMMON SHARES
Basic Shares Outstanding	495.9M shares	462.3M
Diluted Shares Outstanding	495.9M shares	462.3M

Balance Sheet

Concept	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$314.4M
YoY Change		-34.43%
Cash & Equivalents	$170.0M	$314.4M
Short-Term Investments
Other Short-Term Assets	$2.155M	$29.99M
YoY Change	-92.81%	15.21%
Inventory	$14.75M	$11.82M
Prepaid Expenses	$11.77M
Receivables	$1.099M	$4.124M
Other Receivables	$2.538M	$0.00
Total Short-Term Assets	$233.0M	$360.3M
YoY Change	-35.34%	-30.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.62M	$35.70M
YoY Change	-25.44%	-64.53%
Goodwill		$351.7M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.140M	$2.612M
YoY Change	-56.36%	-74.71%
Total Long-Term Assets	$135.1M	$510.9M
YoY Change	-73.56%	-5.81%
TOTAL ASSETS
Total Short-Term Assets	$233.0M	$360.3M
Total Long-Term Assets	$135.1M	$510.9M
Total Assets	$368.0M	$871.2M
YoY Change	-57.75%	-17.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.19M	$12.75M
YoY Change	-12.21%	-29.39%
Accrued Expenses	$64.67M	$50.22M
YoY Change	28.79%	-14.13%
Deferred Revenue	$68.02M
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$152.9M	$118.9M
YoY Change	28.55%	-6.96%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities	$1.500M	$1.388M
YoY Change	8.07%	-98.27%
Total Long-Term Liabilities	$1.500M	$1.388M
YoY Change	8.07%	-98.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$152.9M	$118.9M
Total Long-Term Liabilities	$1.500M	$1.388M
Total Liabilities	$224.5M	$195.7M
YoY Change	14.73%	-5.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.242B	-$1.611B
YoY Change	39.2%
Common Stock	$2.386B	$2.287B
YoY Change	4.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$143.5M	$675.5M
YoY Change
Total Liabilities & Shareholders Equity	$368.0M	$871.2M
YoY Change	-57.75%	-17.98%

Cashflow Statement

Concept	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$69.40M	-$104.6M
YoY Change	-33.67%	16.86%
Depreciation, Depletion And Amortization	$2.000M	$3.000M
YoY Change	-33.33%	-68.13%
Cash From Operating Activities	-$43.27M	-$69.36M
YoY Change	-37.61%	-5.05%
INVESTING ACTIVITIES
Capital Expenditures	$366.0K	$419.0K
YoY Change	-12.65%	-114.45%
Acquisitions
YoY Change
Other Investing Activities	$148.0K	$5.000K
YoY Change	2860.0%
Cash From Investing Activities	-$1.156M	-$2.695M
YoY Change	-57.11%	-7.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$9.000K	-114.0K
YoY Change	-107.89%	-107.44%
NET CHANGE
Cash From Operating Activities	-$43.27M	-69.36M
Cash From Investing Activities	-$1.156M	-2.695M
Cash From Financing Activities	$9.000K	-114.0K
Net Change In Cash	-$44.42M	-72.50M
YoY Change	-38.73%	-2.57%
FREE CASH FLOW
Cash From Operating Activities	-$43.27M	-$69.36M
Capital Expenditures	$366.0K	$419.0K
Free Cash Flow	-$43.64M	-$69.77M
YoY Change	-37.46%	-0.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	dei	Document Type DocumentType	10-Q
CY2024Q2	dei	Entity File Number EntityFileNumber	001-39587
CY2024Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001804591
CY2024Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2024Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q2	dei	Amendment Flag AmendmentFlag	false
CY2024Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q2	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q2	dei	Entity Registrant Name EntityRegistrantName	23ANDME HOLDING CO
CY2024Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
CY2024Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2024Q2	dei	City Area Code CityAreaCode	650
CY2024Q2	dei	Local Phone Number LocalPhoneNumber	938-6300
CY2024Q2	dei	Trading Symbol TradingSymbol	ME
CY2024Q2	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q2	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2024Q2	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q2	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169971000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	216488000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1499000	usd
CY2024Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	1399000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1099000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3324000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	14747000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	12465000	usd
CY2024Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	5046000	usd
CY2024Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	4792000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40592000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16841000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	232954000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	255309000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26620000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28351000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	47016000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	48894000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8974000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	6974000	usd
CY2024Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	20068000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	20516000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	31275000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	33255000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	675490000	usd
CY2024Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	48000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17923000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-69400000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	143504000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	713939000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	85000	usd
CY2023Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	121000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	47915000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-334000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-104624000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-69400000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-104624000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3987000	usd
CY2024Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-1240344
CY2024Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	349 Oyster Point Boulevard
CY2024Q2	dei	Security12b Title Security12bTitle	Class A common stock, $0.0001 par value per share
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1140000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1868000	usd
CY2024Q2	us-gaap	Assets Assets	368047000	usd
CY2024Q1	us-gaap	Assets Assets	395167000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11192000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11571000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	64673000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42263000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	68015000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	64827000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8977000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8670000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	152857000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	127331000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10000000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	65186000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	67845000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1500000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1471000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	224543000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	206647000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	51000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	49000	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2385941000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2361559000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2242488000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2173088000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	143504000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	188520000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	368047000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	395167000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40414000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	60864000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	19900000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	30184000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	20514000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	30680000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44637000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62329000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15472000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	22658000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32360000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50740000	usd
CY2024Q2	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2023Q2	us-gaap	Restructuring Charges RestructuringCharges	4217000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	92469000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	139944000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-71955000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-109264000	usd
CY2024Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2574000	usd
CY2023Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	4307000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	333000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69400000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-104624000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-69400000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-104624000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-334000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69400000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-104958000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.14
CY2024Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.14
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.23
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.23
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	495892915	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	495892915	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	462254442	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	462254442	shares
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	188520000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	58000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6868000	usd
CY2024Q2	me	Amortization And Impairment Of Internal Use Software AmortizationAndImpairmentOfInternalUseSoftware	1799000	usd
CY2023Q2	me	Amortization And Impairment Of Internal Use Software AmortizationAndImpairmentOfInternalUseSoftware	1248000	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	21577000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	51100000	usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	44000	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	5000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2226000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2227000	usd
CY2024Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2283000	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1568000	usd
CY2024Q2	me	Increase Decrease In Deferred Cost Of Revenue IncreaseDecreaseInDeferredCostOfRevenue	-254000	usd
CY2023Q2	me	Increase Decrease In Deferred Cost Of Revenue IncreaseDecreaseInDeferredCostOfRevenue	-1925000	usd
CY2024Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-378000	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1928000	usd
CY2024Q2	me	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	1878000	usd
CY2023Q2	me	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	1749000	usd
CY2024Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-728000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-408000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-309000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2000	usd
CY2024Q2	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	581000	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1889000	usd
CY2024Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1812000	usd
CY2023Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-14398000	usd
CY2024Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2351000	usd
CY2023Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2070000	usd
CY2024Q2	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	29000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-92000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43270000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69355000	usd
CY2024Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	366000	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	419000	usd
CY2024Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	148000	usd
CY2023Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5000	usd
CY2024Q2	us-gaap	Payments For Software PaymentsForSoftware	938000	usd
CY2023Q2	us-gaap	Payments For Software PaymentsForSoftware	2281000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1156000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2695000	usd
CY2024Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	58000	usd
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	69000	usd
CY2024Q2	me	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	1000	usd
CY2023Q2	me	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	62000	usd
CY2024Q2	me	Payments For Taxes Related To Net Share Settlement Of Equity Awards PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards	-48000	usd
CY2023Q2	me	Payments For Taxes Related To Net Share Settlement Of Equity Awards PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards	-121000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-114000	usd
CY2024Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-334000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-44417000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-72498000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	224861000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	395222000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180444000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	322724000	usd
CY2024Q2	me	Purchases Of Property And Equipment During The Period Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentDuringThePeriodIncludedInAccountsPayableAndAccruedExpenses	111000	usd
CY2023Q2	me	Purchases Of Property And Equipment During The Period Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentDuringThePeriodIncludedInAccountsPayableAndAccruedExpenses	176000	usd
CY2024Q2	me	Stock Based Compensation Capitalized For Internal Use Software Costs StockBasedCompensationCapitalizedForInternalUseSoftwareCosts	414000	usd
CY2023Q2	me	Stock Based Compensation Capitalized For Internal Use Software Costs StockBasedCompensationCapitalizedForInternalUseSoftwareCosts	1188000	usd
CY2024Q2	me	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	0	usd
CY2023Q2	me	Deferred Offering Costs Included In Accounts Payable And Accrued Expenses DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses	100000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169971000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	314351000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1499000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1399000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8974000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	6974000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180444000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	322724000	usd
CY2024Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	reportable_segment
CY2024Q2	us-gaap	Fiscal Period FiscalPeriod	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fiscal Year</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s fiscal year ends on March 31. References to fiscal 2025 refer to the fiscal year ending March 31, 2025 and references to fiscal 2024 and fiscal 2023 refer to the fiscal years ended March 31, 2024 and March 31, 2023, respectively.</span></div>
CY2024Q2	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period and the accompanying notes. Significant items subject to such estimates and assumptions include, but are not limited to the determination of standalone selling price for various performance obligations; the estimated expected benefit period for the rate and recognition pattern of breakage revenue for purchases where a saliva collection kit (“kit”) is never returned for processing; the capitalization and estimated useful life of internal use software; the useful life of long-lived assets; fair value of intangible assets acquired in business combinations; the incremental borrowing rate for operating leases; stock-based compensation including the determination of the fair value of stock options and annual incentive bonuses payable in the form of restricted stock units (“RSUs”); the assumptions used in going concern assessments; and the valuation of deferred tax assets and uncertain tax positions. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from these estimates, and such differences could be material to the condensed consolidated financial statements.</span></div>The Company is not aware of any specific event or circumstance that would require revisions to estimates, updates to judgments, or adjustments to the carrying value of assets or liabilities. These estimates may change, as new events occur and/or additional information is obtained, and will be recognized in the condensed consolidated financial statements as soon as they become known.
CY2024Q2	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentration of Credit Risk</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to a concentration of credit risk include cash, cash equivalents, and accounts receivable. The Company maintains a majority of its cash and cash equivalents with a single high-quality financial institution, the composition and maturities of which are regularly monitored by the Company. The Company’s revenue and accounts receivable are derived primarily from the United States. See Note 3, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue,</span>” for additional information regarding geographical disaggregation of revenue. The Company grants credit to its customers in the normal course of business, performs credit evaluations of its significant customers on an as-needed basis, and does not require collateral. Concentrations of credit risk are limited as the Company’s trade receivables are primarily related to third parties, which collect its credit card receivables, and large multinational corporations. The Company regularly monitors the aging of accounts receivable balances.
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	10500000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	8400000	usd
CY2023Q2	me	Increase Decrease In Escrow Deposit IncreaseDecreaseInEscrowDeposit	-6000000	usd
CY2024Q2	me	Increase Decrease In Escrow Deposit IncreaseDecreaseInEscrowDeposit	6200000	usd
CY2024	me	Proceeds From Reverse Recapitalization Transaction ProceedsFromReverseRecapitalizationTransaction	309700000	usd
CY2024	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	250000000.0	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	170000000.0	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40414000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	60864000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40414000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	60864000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	4000000.0	usd
CY2023Q2	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	4600000	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.69
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2024Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	reportable_segment
CY2024Q2	us-gaap	Revenues Revenues	40414000	usd
CY2023Q2	us-gaap	Revenues Revenues	60864000	usd
CY2024Q2	me	Adjusted Ebitda AdjustedEBITDA	-35162000	usd
CY2023Q2	me	Adjusted Ebitda AdjustedEBITDA	-49800000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-69400000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-104624000	usd
CY2024Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2574000	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4307000	usd
CY2024Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-19000	usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	333000	usd
CY2024Q2	me	Depreciation And Amortization Net DepreciationAndAmortizationNet	4011000	usd
CY2023Q2	me	Depreciation And Amortization Net DepreciationAndAmortizationNet	4478000	usd
CY2024Q2	me	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	1776000	usd
CY2023Q2	me	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	3638000	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	21577000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	51100000	usd
CY2024Q2	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	usd
CY2023Q2	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-248000	usd
CY2024Q2	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	9429000	usd
CY2023Q2	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	usd
CY2024Q2	me	Adjusted Ebitda Net AdjustedEBITDANet	-35162000	usd
CY2023Q2	me	Adjusted Ebitda Net AdjustedEBITDANet	-49800000	usd
CY2024	me	Fair Value Assets Level Two To Level One Transfers Amount FairValueAssetsLevelTwoToLevelOneTransfersAmount	0	usd
CY2024Q2	me	Fair Value Assets Level Two To Level One Transfers Amount FairValueAssetsLevelTwoToLevelOneTransfersAmount	0	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11771000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9296000	usd
CY2024Q2	us-gaap	Loss Contingency Receivable Current LossContingencyReceivableCurrent	24128000	usd
CY2024Q1	us-gaap	Loss Contingency Receivable Current LossContingencyReceivableCurrent	2188000	usd
CY2024Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2538000	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3563000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2155000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1794000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40592000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16841000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	109994000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	110082000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	83374000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	81731000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26620000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28351000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	2000000.0	usd
CY2023Q2	us-gaap	Depreciation Depreciation	3000000	usd
CY2024Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q2	me	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	85166000	usd
CY2024Q1	me	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	85166000	usd
CY2024Q2	me	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	38150000	usd
CY2024Q1	me	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	36272000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	47016000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	48894000	usd
CY2024Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	37270000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	35918000	usd
CY2024Q2	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	17202000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	15402000	usd
CY2024Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	20068000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	20516000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	67300000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	36025000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	31275000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	67300000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	34045000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	33255000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3800000	usd
CY2024Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	5940000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	7919000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	6769000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	5006000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3175000	usd
CY2024Q2	me	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	2466000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	31275000	usd
CY2024Q2	me	Accrued Payables Current AccruedPayablesCurrent	7953000	usd
CY2024Q1	me	Accrued Payables Current AccruedPayablesCurrent	9697000	usd
CY2024Q2	me	Accrued Settlement And Legal Expenses AccruedSettlementAndLegalExpenses	34655000	usd
CY2024Q1	me	Accrued Settlement And Legal Expenses AccruedSettlementAndLegalExpenses	3260000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3952000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4266000	usd
CY2024Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	7185000	usd
CY2024Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	7221000	usd
CY2024Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	4459000	usd
CY2024Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	7420000	usd
CY2024Q2	me	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	5294000	usd
CY2024Q1	me	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	9291000	usd
CY2024Q2	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	1175000	usd
CY2024Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	1108000	usd
CY2024Q2	me	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	64673000	usd
CY2024Q1	me	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	42263000	usd
CY2023Q2	us-gaap	Restructuring Charges RestructuringCharges	4200000	usd
CY2024Q2	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2024Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	22000	usd
CY2024Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2024Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	22000	usd
CY2024Q2	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2024Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	22000	usd
CY2024Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2024Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	3300000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	3400000	usd
CY2024Q2	us-gaap	Variable Lease Cost VariableLeaseCost	1500000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	1300000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	10416000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15946000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15472000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11666000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	12016000	usd
CY2024Q2	me	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	29413000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	94929000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	20766000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	74163000	usd
CY2024Q2	us-gaap	Purchase Obligation PurchaseObligation	64400000	usd
CY2024Q2	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	Each share of Class B common stock is convertible into one share of Class A common stock any time at the option of the holder and is automatically converted into one share of Class A common stock upon transfer
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	64832199	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	70739770	shares
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	223027929	shares
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	238918589	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	70739770	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.68
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	306000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2024Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	137776	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.42
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	5769795	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.71
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	64832199	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.60
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	61000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	50032139	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.99
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y1M6D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	61000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.43
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	22200000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21577000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	51100000	usd
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2024Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2024Q2	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2024Q2	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.02
CY2024Q2	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2024Q2	me	Defined Contribution Plan Employer Matching Contribution Employees Gross Pay Amount DefinedContributionPlanEmployerMatchingContributionEmployeesGrossPayAmount	2300000	usd
CY2024Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000	usd
CY2023Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	900000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001804591-24-000047-index-headers.html	Edgar Link	pending
0001804591-24-000047-index.html	Edgar Link	pending
0001804591-24-000047.txt	Edgar Link	pending
0001804591-24-000047-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
me-20240630.htm	Edgar Link	pending
me-20240630.xsd	Edgar Link	pending
me-20240630xex311.htm	Edgar Link	pending
me-20240630xex312.htm	Edgar Link	pending
me-20240630xex321.htm	Edgar Link	pending
me-20240630xex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
me-20240630_cal.xml	Edgar Link	unprocessable
me-20240630_def.xml	Edgar Link	unprocessable
me-20240630_lab.xml	Edgar Link	unprocessable
me-20240630_pre.xml	Edgar Link	unprocessable
me-20240630_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ME
23andMe Holding Co. Stock $me

2024 Q2 Form 10-Q Financial Statement

#000180459124000047 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ME 23andMe Holding Co. Stock $me

2024 Q2 Form 10-Q Financial Statement

#000180459124000047 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ME
23andMe Holding Co. Stock $me